Welcome to CDC stacks | Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs - 18080 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs
  • Published Date:
    Mar 2010
  • Source:
    Emerg Infect Dis. 16(3):493-496.
Filetype[PDF-199.60 KB]


No Related Documents.
You May Also Like:
  1. Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
    Personal Author:
    Hoopes, Justin D.; Driebe, Elizabeth M.; Kelley, Erin; Engelthaler, David M.; Keim, Paul S.; Perelson, Alan S.; Rong, Libin; Went, Gregory T.; Nguyen, Jack T.;
    Published:
    Dec 29 2011
    Source:
    PLoS One. 2011; 6(12).
    Description:
    Widespread resistance among circulating influenza A strains to at least one of the anti-influenza drugs is a major public health concern. A triple combination antiviral drug (TCAD) regimen comprised of amantadine, oseltamivir, and ribavirin has been ...
    File Type:
    Filetype[PDF - 582.83 KB]
  2. Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective
    Personal Author:
    Okomo-Adhiambo, Margaret; Sleeman, Katrina; Ballenger, Kristina; Nguyen, Ha T.; Mishin, Vasiliy P.; Sheu, Tiffany G.; Smagala, James; Li, Yan; Klimov, Alexander I.; Gubareva, Larisa V.;
    Published:
    Oct 13 2010
    Source:
    Viruses. 2010; 2(10):2269-2289.
    Description:
    Neuraminidase inhibitors (NAIs) are vital in managing seasonal and pandemic influenza infections. NAI susceptibilities of virus isolates (n = 5540) collected during the 2008-2009 influenza season were assessed in the chemiluminescent neuraminidase in...
    File Type:
    Filetype[PDF - 419.41 KB]
  3. Influenza B Viruses with Mutation in the Neuraminidase Active Site, North Carolina, USA, 2010–11
    Personal Author:
    Sleeman, Katrina; Sheu, Tiffany G.; Moore, Zack; Kilpatrick, Susan; Garg, Shikha; Fry, Alicia M.; Gubareva, Larisa V.;
    Published:
    Nov 2011
    Source:
    Emerg Infect Dis. 17(11):2043-2046.
    Description:
    Oseltamivir is 1 of 2 antiviral medications available for the treatment of influenza B virus infections. We describe and characterize a cluster of influenza B viruses circulating in North Carolina with a mutation in the neuraminidase active site that...
    File Type:
    Filetype[PDF - 303.27 KB]
  4. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
    Personal Author:
    Okomo-Adhiambo, Margaret; Nguyen, Ha T.; Abd Elal, Anwar; Sleeman, Katrina; Fry, Alicia M.; Gubareva, Larisa V.;
    Published:
    Dec 02 2013
    Source:
    Influenza Other Respir Viruses. 2013; 8(2):258-265.
    Description:
    Background : Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpr...
    File Type:
    Filetype[PDF - 117.95 KB]
  5. Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Bridges, Carolyn B.; Cox, Nancy (Nancy J.); Fukuda, Keiji; Singleton, James A.; Strikas, Raymond A.; Winquist, Andrea.;
    Corporate Author:
    United States, Advisory Committee on Immunization Practices.. Centers for Disease Control and Prevention (U.S.). National Center for Infectious Diseases (U.S.). Division of Viral and Rickettsial Diseases.. National Immunization Program (Centers for Disease Control and Prevention). Epidemiology and Surveillance Division..
    Published:
    April 14, 2000
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 49, no. RR-3
    Description:
    "This report updates 1999 recommendations by the Advisory Committee on Immunization Practices (ACIP) on the use of influenza vaccine and antiviral agents (MMWR 1999;48[No. RR-4]: 1-29). These recommendations include five principal changes: a) th...
    Status:
    superseded
    File Type:
    Filetype[PDF - 288.51 KB]